Allred Capital Management LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 30,296 shares of the company’s stock after buying an additional 244 shares during the period. Johnson & Johnson comprises 2.5% of Allred Capital Management LLC’s portfolio, making the stock its 7th largest holding. Allred Capital Management LLC’s holdings in Johnson & Johnson were worth $4,696,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sierra Capital LLC boosted its position in shares of Johnson & Johnson by 0.6% in the 4th quarter. Sierra Capital LLC now owns 10,036 shares of the company’s stock valued at $1,773,000 after purchasing an additional 61 shares during the period. MTM Investment Management LLC lifted its stake in Johnson & Johnson by 0.5% during the first quarter. MTM Investment Management LLC now owns 11,283 shares of the company’s stock valued at $1,749,000 after buying an additional 61 shares in the last quarter. Lockerman Financial Group Inc. boosted its holdings in shares of Johnson & Johnson by 2.4% in the fourth quarter. Lockerman Financial Group Inc. now owns 2,684 shares of the company’s stock worth $474,000 after buying an additional 62 shares during the period. OneAscent Financial Services LLC raised its holdings in shares of Johnson & Johnson by 3.3% during the first quarter. OneAscent Financial Services LLC now owns 1,986 shares of the company’s stock valued at $308,000 after acquiring an additional 63 shares during the period. Finally, Addison Advisors LLC lifted its position in shares of Johnson & Johnson by 0.8% in the 4th quarter. Addison Advisors LLC now owns 7,862 shares of the company’s stock valued at $1,389,000 after acquiring an additional 64 shares in the last quarter. 67.57% of the stock is currently owned by institutional investors and hedge funds.
Johnson & Johnson Stock Performance
NYSE JNJ opened at $164.54 on Thursday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88. The firm has a market capitalization of $427.63 billion, a price-to-earnings ratio of 33.31, a P/E/G ratio of 2.81 and a beta of 0.54. The company’s fifty day moving average is $166.61 and its two-hundred day moving average is $161.45. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $181.04.
Johnson & Johnson Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be issued a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 2.89%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 96.36%.
Analyst Ratings Changes
A number of research analysts have recently weighed in on JNJ shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Tuesday. Morgan Stanley reiterated an “equal weight” rating and issued a $187.00 target price on shares of Johnson & Johnson in a research report on Friday, July 21st. Credit Suisse Group increased their target price on shares of Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, July 21st. JPMorgan Chase & Co. increased their target price on shares of Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research report on Friday, July 21st. Finally, Citigroup assumed coverage on shares of Johnson & Johnson in a research report on Tuesday, May 30th. They issued a “buy” rating and a $185.00 target price for the company. Eight investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson has an average rating of “Hold” and an average price target of $171.80.
Read Our Latest Research Report on Johnson & Johnson
Insider Activity at Johnson & Johnson
In related news, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the transaction, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the transaction, the executive vice president now owns 65,934 shares in the company, valued at $10,549,440. The disclosure for this sale can be found here. Insiders sold 47,163 shares of company stock valued at $7,928,856 in the last ninety days. Insiders own 0.20% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- What is a Non-Fungible Token (NFT)? Definition and How it Works
- Bear Market vs Recession: What Are the Differences?
- Investing in Commodities: What Are They? How to Invest in Them
- 7 Best AI Mutual Funds (and ETFs) to Sweep the AI Craze
- The Significance of Brokerage Rankings in Stock Selection
- Auto Parts Stocks Shift Gears: Which is the Right One to Buy?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
